2011•European PsychiatryRequires access

Old drugs vs. new drugs: Treating bipolar disorder in children and adolescents

P. Dineen, Andrea L. Malizia

Open publisher page 0 citations

Abstract

This is a literature review of the evidence for pharmacological treatment for bipolar disorder in children and adolescents. The review covers drugs that have controlled studies and is divided into older, classical antimanic drugs and the newer mood-stabliser/antipsychotic drugs. The drugs that have had controlled studies are aripiprazole, lithium, olanzapine, oxcarbazepine, quetiapine, risperidone, topiramate, valproate/divalproex drugs and ziprasidone. Carbamazepine, lamotrigine and nefazodone (which is included for completion) were not found to have any evidence from controlled studies. Of the 9 drugs that have evidence, it was found that the newer second-generation antipsychotics had better evidence for efficacy for management of acute mania in children and adolescents: aripiprazole, risperidone, quetiapine and olanzapine. Classical antimanic agents such as lithium and valproate-based drugs had limited evidence.

About this research paper

What this paper is about

This is a literature review of the evidence for pharmacological treatment for bipolar disorder in children and adolescents. The review covers drugs that have controlled studies and is divided into older, classical antimanic drugs and the newer mood-stabliser/antipsychotic drugs. The drugs that have had controlled studies are aripiprazole, lithium, olanzapine, oxcarbazepine, quetiapine, risperidone, topiramate, valproate/divalproex drugs and ziprasidone. Carbamazepine, lamotrigine and nefazodone (which is included for completion) were not found to have any evidence from controlled studies. Of the 9 drugs that have evidence, it was found that the newer second-generation antipsychotics had better evidence for efficacy for management of acute mania in children and adolescents: aripiprazole, risperidone, quetiapine and olanzapine. Classical antimanic agents such as lithium and valproate-based drugs had limited evidence.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

This is a literature review of the evidence for pharmacological treatment for bipolar disorder in children and adolescents. The review covers drugs that have controlled studies and is divided into older, classical antimanic drugs and the newer mood-stabliser/antipsychotic drugs. The drugs that have had controlled studies are aripiprazole, lithium, olanzapine, oxcarbazepine, quetiapine, risperidone, topiramate, valproate/divalproex drugs and ziprasidone. Carbamazepine, lamotrigine and nefazodone (which is included for completion) were not found to have any evidence from controlled studies. Of the 9 drugs that have evidence, it was found that the newer second-generation antipsychotics had better evidence for efficacy for management of acute mania in children and adolescents: aripiprazole, risperidone, quetiapine and olanzapine. Classical antimanic agents such as lithium and valproate-based drugs had limited evidence.

Key concepts: Quetiapine, Lamotrigine, Ziprasidone, Olanzapine, Oxcarbazepine, Aripiprazole, Risperidone, Topiramate

Related papers

Back to paper searchBrowse research topicsOriginal source
Old drugs vs. new drugs: Treating bipolar disorder in children and adolescents — Research Paper | ScholarLens